心脏骤停后接受ECMO患者的神经预后评估:经典工具是否仍然有效?
本回顾性观察研究纳入397例未接受ECMO和50例接受ECMO的心脏骤停后昏迷成人,比较瞳孔反射、脑电图、体感诱发电位、神经元特异性烯醇化酶等预后指标对死亡和不良功能结局(CPC 3-5分)的预测性能。ECMO组不良功能结局比例更高(74% vs 59%,p=0.040),死亡率无显著差异(60% vs 47%,p=0.080)。除神经元特异性烯醇化酶水平在ECMO组更高(p<0.001)外,各预后指标出现率两组相似,各指标特异性在两组均为92%-100%,至少两项指标组合的特异性在未ECMO组为99.3%、ECMO组为100%,组合的ROC曲线下面积分别为0.822和0.681(p=0.134)。作者认为,在等待更大 cohort 的前瞻性评估前,心脏骤停后昏迷患者中预后因素的表现似乎在ECMO组与未ECMO组相当,尤其至少两项不良结局标准组合在两组均适用。
要点
- ECMO组不良功能结局(CPC 3-5分)比例显著高于未ECMO组(74% vs 59%,p=0.040),死亡率无显著差异(60% vs 47%,p=0.080)。
- 除神经元特异性烯醇化酶水平在ECMO组更高(p<0.001)外,瞳孔反射、脑电图背景和反应性、体感诱发电位、肌阵挛等预后指标出现率两组相似。
- 各预后指标对不良结局的特异性在两组均为92%-100%,至少两项指标组合的特异性在未ECMO组为99.3%、ECMO组为100%。
- 组合指标预测不良结局的ROC曲线下面积在未ECMO组为0.822、ECMO组为0.681(p=0.134),ECMO组数值较低但差异未达统计学显著。
适用人群与场景
- 连续纳入的心脏骤停后昏迷成人,来自本中心注册研究。
- 排除标准:36小时内死亡且未进行预后测试的患者。
- 接受静脉-动脉ECMO的条件:年龄<80岁、难治性心脏骤停、无血流时间<5分钟、入院时低血流时间≤60分钟。
诊断标准与关键阈值
- 不良功能结局定义为脑功能分类(CPC)评分3-5分。
- 预后指标包括瞳孔反射、脑电图、体感诱发电位、神经元特异性烯醇化酶。
- 至少两项不良结局指标同时出现作为组合标准。
研究设计与关键结果
- 回顾性观察研究,纳入397例未接受ECMO和50例接受ECMO的心脏骤停后昏迷成人。
- 中位年龄65岁(四分位距54-74),男性占69.8%,心脏病因占67.6%,可电击心律占52%,恢复有效循环中位时间20分钟(四分位距10-28)。
- ECMO组不良功能结局(CPC 3-5分)比例74%,未ECMO组59%(p=0.040);死亡率ECMO组60%,未ECMO组47%(p=0.080)。
- 神经元特异性烯醇化酶水平在ECMO组更高(p<0.001)。
- 各预后指标对不良结局的特异性在两组均为92%-100%;至少两项指标组合的特异性在未ECMO组为99.3%,ECMO组为100%。
- 组合指标预测不良结局的ROC曲线下面积在未ECMO组为0.822,ECMO组为0.681(p=0.134)。
证据类型、等级与局限
- 证据类型:回顾性观察研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在等待更大 cohort 的前瞻性评估前,心脏骤停后昏迷患者中预后因素的表现似乎在ECMO组与未ECMO组相当。
- 作者认为,至少两项不良结局标准组合在ECMO组和未ECMO组均适用。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: According to international guidelines, neuroprognostication in comatose patients after cardiac arrest (CA) is performed using a multimodal approach. However, patients undergoing extracorporeal membrane oxygenation (ECMO) may have longer pharmacological sedation and show alteration in biological markers, potentially challenging prognostication. Here, we aimed to assess whether routinely used predictors of poor neurological outcome also exert an acceptable performance in patients undergoing ECMO after CA.
METHODS: This observational retrospective study of our registry includes consecutive comatose adults after CA. Patients deceased within 36 h and not undergoing prognostic tests were excluded. Veno-arterial ECMO was initiated in patients < 80 years old presenting a refractory CA, with a no flow < 5 min and a low flow ≤ 60 min on admission. Neuroprognostication test performance (including pupillary reflex, electroencephalogram, somatosensory-evoked potentials, neuron-specific enolase) toward mortality and poor functional outcome (Cerebral Performance Categories [CPC] score 3-5) was compared between patients undergoing ECMO and those without ECMO.
RESULTS: We analyzed 397 patients without ECMO and 50 undergoing ECMO. The median age was 65 (interquartile range 54-74), and 69.8% of patients were men. Most had a cardiac etiology (67.6%); 52% of the patients had a shockable rhythm, and the median time to return of an effective circulation was 20 (interquartile range 10-28) minutes. Compared with those without ECMO, patients receiving ECMO had worse functional outcome (74% with CPC scores 3-5 vs. 59%, p = 0.040) and a nonsignificant higher mortality (60% vs. 47%, p = 0.080). Apart from the neuron-specific enolase level (higher in patients with ECMO, p < 0.001), the presence of prognostic items (pupillary reflex, electroencephalogram background and reactivity, somatosensory-evoked potentials, and myoclonus) related to unfavorable outcome (CPC score 3-5) in both groups was similar, as was the prevalence of at least any two such items concomitantly. The specificity of each these variables toward poor outcome was between 92 and 100% in both groups, and of the combination of at least two items, it was 99.3% in patients without ECMO and 100% in those with ECMO. The predictive performance (receiver operating characteristic curve) of their combination toward poor outcome was 0.822 (patients without ECMO) and 0.681 (patients with ECMO) (p = 0.134).
CONCLUSIONS: Pending a prospective assessment on a larger cohort, in comatose patients after CA, the performance of prognostic factors seems comparable in patients with ECMO and those without ECMO. In particular, the combination of at least two poor outcome criteria appears valid across these two groups.
参考来源
- Ben-Hamouda N, Ltaief Z, Kirsch M, et al. Neuroprognostication Under ECMO After Cardiac Arrest: Are Classical Tools Still Performant? Neurocrit Care. 2022. PMID: 35534658. doi:10.1007/s12028-022-01516-0
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。